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Abstract
Pyridoxal 59-phosphate (PLP) is a cofactor for dozens of B6 requiring enzymes. PLP reacts with apo-B6 enzymes by forming
an aldimine linkage with the e-amino group of an active site lysine residue, thus yielding the catalytically active holo-B6
enzyme. During protein turnover, the PLP is salvaged by first converting it to pyridoxal by a phosphatase and then back to
PLP by pyridoxal kinase. Nonetheless, PLP poses a potential toxicity problem for the cell since its reactive 49-aldehyde
moiety forms covalent adducts with other compounds and non-B6 proteins containing thiol or amino groups. The
regulation of PLP homeostasis in the cell is thus an important, yet unresolved issue. In this report, using site-directed
mutagenesis, kinetic, spectroscopic and chromatographic studies we show that pyridoxal kinase from E. coli forms a
complex with the product PLP to form an inactive enzyme complex. Evidence is presented that, in the inhibited complex,
PLP has formed an aldimine bond with an active site lysine residue during catalytic turnover. The rate of dissociation of PLP
from the complex is very slow, being only partially released after a 2-hour incubation with PLP phosphatase. Interestingly,
the inactive pyridoxal kinaseNPLP complex can be partially reactivated by transferring the tightly bound PLP to an apo-B6
enzyme. These results open new perspectives on the mechanism of regulation and role of pyridoxal kinase in the Escherichia
coli cell.
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for PL kinase (reaction 6). PL kinase, PNP oxidase and PLP
phosphatase constitute the salvage pathway.
PLP is a reactive compound because the 49-aldehyde forms
aldimines with a-amines of amino acids and other compounds
containing amino groups, the e-amino group of lysine residues on
non-B6 proteins, and thiazolidine adducts with sulfhydryl groups
like cysteine. PL, which also contains the 49-aldehyde moiety is
much less reactive than PLP, since its aldehyde group, in aqueous
solution and at neutral pH, exists mostly in the hydrated form
[6,7]. This reactivity of PLP poses two problems for the cell. First,
to keep the cellular level of free PLP low so that it does not react
with other nucleophiles, especially non B6-enzymes, and second, to
supply enough PLP for the dozens of newly synthesized apo-B6
enzymes to form catalytically active holo-B6 enzymes. Some have
proposed that the level of PLP is regulated and kept low by being
an effective feedback inhibitor of both PL kinase [8] and PNP
oxidase [9–15]. We report here on properties of E. coli PL kinase
showing that PLP serves as a slow tight binding inhibitor of the
enzyme.
The structure of PL kinase has been determined from several
sources [11,16–19]. In E. coli there are two PL kinases referred to

Introduction
Pyridoxal 59-phosphate (PLP) is a cofactor for dozens of
enzymes in the E. coli cell that are important in amino acid
metabolism, as well as in several other pathways [1]. A de novo
pathway for PLP biosynthesis occurs in E. coli, but a more
important salvage pathway operates to recycle PLP during protein
turnover [2]. The regulation of PLP homeostasis in E. coli and how
each of the dozens of PLP requiring apo-B6 enzymes competes for
available PLP, to form the catalytically active holo-B6 enzymes,
are important unresolved problems.
Key reactions for maintaining PLP levels in the cell are
shown in Figure 1. The biosynthetic pathway results in the
formation of pyridoxine 59-phosphate (PNP, reaction 1), which
is converted to PLP by the flavin enzyme PNP oxidase (reaction
2) [3]. PLP adds to newly synthesized apo-B6 enzymes
converting them to the catalytically active holo enzymes
(reaction 3). PLP is released during protein turnover of B6
enzymes (reaction 4) and is converted to pyridoxal (PL) by
cellular phosphatases (reaction 5) [3–5]. The formed PL is
phosphorylated back to PLP by pyridoxal kinase (PL kinase)
(reaction 6) [3]. Pyridoxine and pyridoxamine are also substrates
PLoS ONE | www.plosone.org

1

July 2012 | Volume 7 | Issue 7 | e41680

PLP Is an Inhibitor of Pyridoxal Kinase

Figure 1. Vitamin B6 metabolism. A) Reactions in B6 metabolism. Reaction 1, enzymes involved in the de novo biosynthesis of pyridoxine 59phosphate (PNP); Reaction 2, PNP oxidase; Reaction 3, reaction of apo-B6 enzymes with PLP to form active holo-B6 enzymes; Reaction 4, degradation of
holo-B6 enzymes to amino acids and PLP; Reaction 5, PLP phosphatase; Reaction 6, PL kinase. B) Structures of B6 vitamers.
doi:10.1371/journal.pone.0041680.g001

solutions, we calculated 5020 M21 cm21 to be the difference
between the 388 nm molar extinction coefficients of the produced
PLP and the consumed PL. The assay solution contained 1 mM
MgATP, 1 mM PL and 0.9 mM ePL kinase. The rate of PLP
formation decreased exponentially and after about 2 min the
activity was near zero, with only 22 mM PLP being formed. The
apparent rate of activity loss was around 1.5 min21. Since a large
excess of MgATP and PL was present in the assay, and the
reaction is essentially irreversible, the termination of activity
should not be the result of exhaustion of either substrate. However,
it could be the result of product inhibition by ADP and PLP. To
test if this was the reason for loss of activity, we added a second
and equal amount of ePL kinase to the cuvette. The increase in
absorbance at 388 nm resumed at the same rate as observed with
the first addition of ePL kinase, showing that product inhibition
was not the reason for the loss of activity, since at this point PLP is
present in the reaction mixture. Furthermore, this second
measurable activity also exponentially decreased at a rate of
1.5 min21, so that after about 2 min there was no further increase
in PLP production (Fig. 2). A third addition resulted in the same

as PL kinase1 and PL kinase2 [13,20–22]. The activity of PL
kinase2 is very low and there is a question if its function in the cell
is to convert PL to PLP or if it is the enzyme for another unknown
reaction. We have determined the structure and properties of both
E. coli enzymes [11,13]. This study reports on the properties of
only E. coli PL kinase1 and we refer to it as ePL kinase. During our
kinetic measurements, we observed that the enzyme rapidly loses
activity as it catalyzes the conversion of PL and ATP into PLP and
ADP. The reason for this inhibition is the subject of this report.

Results
Inactivation of ePL Kinase during Catalytic Turnover
During our assay of ePL kinase to determine kinetic constants
we observed a rapid loss of activity making kinetic studies from
initial rates difficult. Figure 2 shows a typical assay for production
of PLP. The rate of PLP formation is determined from the
absorbance change at 388 nm. At pH 7.5, used in the assay, both
PL and PLP have an absorption maximum at 388 nm, however,
the extinction coefficient of PLP is much higher. From standard
PLoS ONE | www.plosone.org
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behavior (data not shown). The total absorbance change at
388 nm was the same for each addition of ePL kinase, showing
that the amount of PLP produced was the same. We calculated the
amount of PLP formed before the enzyme lost activity to be
22 mM, determined by dividing the absorbance change at 388 nm
by 5020 M21 cm21. Since we also knew the concentration of the
enzyme we could determine that about 25 catalytic turnovers were
made before the enzyme was inactivated.
This experiment suggests that the loss of activity is the result of a
partition between product release and an inactivation reaction.

Properties of Inactive ePL Kinase
In order to check if the observed inhibition was reversible, we
incubated ePL kinase (300 mM) with PL (400 mM) and MgATP
(1 mM) for one hour at 37uC. The protein was then separated
from excess substrates and products by size exclusion chromatography on a Sephadex G-50 column. As shown in Figure 3, the
fractions containing the protein showed an absorbance at 388 nm
(beside the 280 nm absorption peak), suggesting that PLP was
bound to ePL kinase. Addition of NaOH to a final concentration of
0.2 M to the protein samples resulted in a spectrum identical to
the spectrum of PLP in alkaline solution (data not shown). From
the observed absorbance maxima at 388 nm and 278 nm for PLP
and protein, respectively, we determined that the stoichiometry of
PLP to ePL kinase subunits was 1:1.
What is of interest in the elution profile shown in Figure 3 is the
lack of a tailing edge in the 388 nm absorption profile of the
chromophore that co-elutes with the protein in the size-exclusion
chromatography. This suggests that the complex between protein
and PLP is very tight and does not readily dissociate upon the slow
migration of the ePL kinase down the sizing column. The spectrum
of a typical fraction containing protein-bound PLP is shown in the
inset of Figure 3 and exhibits two distinct absorbance maxima at
336 nm and 420 nm. The band with maximum at 420 nm is
characteristic of PLP bound as an aldimine [23]. The aldimine
linkage (or Schiff base) between PLP and a lysine residue is a
reversible covalent bond. It is characteristic of PLP bound to an eamino group of an active site lysine residue in holo-B6 enzymes
[24].

Figure 3. Formation of an ePL kinaseNPLP complex. ePL kinase
(300 mM) was incubated with MgATP (1 mM), PL (400 mM) and MgCl2
(0.2 mM) for 1 hour at 37uC in a volume of 2 ml. Then it was added to a
0.6 mm645 cm column of Sephadex G-50 equilibrated with 1 mM
MgATP in reaction buffer and eluted with equilibration solution.
Aliquots of 400 ml were collected and absorbance at 278 nm (ePL
kinase) and 388 nm (PLP) was recorded. Inset: spectrum of ePL kinase
with bound PLP showing that the bound PLP exhibits absorbance peaks
at 336 nm and 420 nm.
doi:10.1371/journal.pone.0041680.g003

Rate of Formation of ePL KinaseNPLP Complex
The considerable separation between the ePL kinaseNPLP
complex and free PLP, shown in Figure 3, provides a method to
rapidly separate the enzyme from unbound substrates and
products by using small spin columns (see Experimental Procedure). To determine the rate at which the complex was formed,
ePL kinase (90 mM) was incubated with 400 mM MgATP and
150 mM PL at 37uC from 2 to 25 min. At several time intervals, a
sample of the reaction mixture was removed and added to a small
spin Sephadex G-50 column, kept at 4uC, to rapidly separate
enzyme-bound PLP from unbound small molecules. The absorbance of the eluted enzyme at 420 nm and 336 nm was measured
to determine the amount of bound PLP and the percentage of
saturation per enzyme subunit. As shown in Figure 4 (open circle)
the amount of bound PLP reached about 100% of saturation in
about 10 minutes, with 50% saturation occurring in less than
2 min. However, if ePL kinase was incubated with 150 mM PLP, in
place of PL, and 400 mM MgATP the amount of bound PLP after
10 minutes was about 60% and reached only 80% of saturation in
25 min. In this case, it took about 7.5 min to reach 50% saturation
(Fig. 4, solid circle). This shows that PLP generated by enzyme
turnovers leads to faster formation of the complex compared to
when PLP is added as an external ligand.
The ePL kinase concentration in the previous experiment with
PL and MgATP is high and the amount of time required to
process the reaction would convert much of the PL to PLP and an
equivalent amount of the MgATP to MgADP, suggesting that the
complex may contain both PLP and MgADP. The experiment
was repeated with PLP and MgADP, and the rate of formation of
the complex was similar to the rate observed with PL and MgATP
(Table 1). On the other hand, when PLP and Mg2+ were used in
the absence of any nucleotide the rate was slower and comparable
to the rate observed with PLP and MgATP, shown in Figure 4
(Table 1). This suggests that a tight complex is formed with PLP
and MgADP. The spectrum of the ePL kinaseNPLP complexes in
these experiments was the same as shown in the inset of Figure 3.
Keeping in mind that ePL kinase also phosphorylates PN and
PM, we repeated the same experiments described above, to
determine if PNP and PMP also formed a tight complex with ePL

Figure 2. Kinetics of ePL kinase inhibition. The formation of PLP
by ePL kinase was followed at 388 nm in 400 ml of reaction solution
containing 1 mM MgATP, 0.2 mM MgCl2, and 1 mM PL at 37uC. At the
first arrow, ePL kinase was added to 0.9 mM and PLP formation followed
for about 120 seconds. A second aliquot of ePL kinase was added at the
second arrow.
doi:10.1371/journal.pone.0041680.g002
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Table 2. Measurement of nucleotides in the ePL kinaseNPLP
complexesa.

%PLP

%ATP

%ADP

PL

MgATP

MgCl2

95

n.d.b

21

PLP

MgATP

MgCl2

100

n.d.

n.d.

PLP

MgADP

MgCl2

72

n.d.

43

PLP

–

MgCl2

82

–

–

PLP

–

–c

51

–

–

a

ePL kinase (130 mM) samples were incubated with different combinations of PL
(0.5 mM), PLP (0.5 mM), MgATP (1 mM), MgADP (1 mM) and MgCl2 (0.5 mM) for
one hour at 37uC. These samples were then passed through a sizing column
and the fractions containing the enzyme were collected and analyzed with
respect to PLP and nucleotides content. The values reported in the table are
percentages of saturation with respect to enzyme subunits.
b
n.d.: not detectable with the method employed (minimum detectable level
1.5 mM; see Experimental Procedures for details).
c
MgCl2 was also omitted from the chromatography equilibration and elution
buffer.
doi:10.1371/journal.pone.0041680.t002

Figure 4. Rate of formation of ePL kinaseNPLP complex. To a
series of 100 ml solutions in Eppendorf vials containing 0.4 mM MgATP,
0.20 mM MgCl2 and either 0.150 mM PL or 0.150 mM PLP at 37uC was
added 9 nmoles of ePL kinase (90 mM). After 2, 5, 15 and 25 min
contents of vials were withdrawn and placed on small Sephadex G-50
columns at 4uC equilibrated with 1 mM MgATP and 0.2 mM MgCl2 (see
Experimental Procedures) to separate bound and free PLP. The eluate of
each column was 400 ml. Spectra were recorded and the absorbance at
420 nm determined. Open circles, reactions initiated with PL, closed
circles reactions initiated with PLP. The lines through the experimental
points are those obtained from nonlinear least squares fittings of data
to an exponential equation which gave rate constants of 0.4 min21 and
0.1 min21 and amplitudes of 100% and 83% for the experiments
initiated with PL and PLP, respectively.
doi:10.1371/journal.pone.0041680.g004

kinase. Our results showed that a 25 min incubation at 37uC
resulted in no detectable complex formation with these two
vitamers (data not shown).

ATP was not detected in any of the analyzed complexes. On the
other hand, ADP was present in the complexes, but not in a
stoichiometric concentration with respect to enzyme subunits.
Apparently, ADP is not bound as tightly as PLP to ePL kinase.
PLP, in the absence of nucleotides or MgCl2, binds tightly to ePL
kinase, although its binding is further promoted by the inclusion of
exogenous MgCl2, suggesting that Mg2+ plays a role in forming the
tight complex (Table 2). These results show that the tight complex
in the presence of nucleotides is actually ePL kinaseNPLPNMgADP.
However, in the following experiments we focused our attention
on the PLP moiety of the complex and therefore will refer to the
ePL kinaseNPLP complex.

Nucleotide Ligands in the ePL KinaseNPLP Complex

Rate of Dissociation of the ePL KinaseNPLP Complex

The experiments described in the previous section had either
MgATP or MgADP present at all times during the chromatographic separation of free PLP from the kinaseNPLP complex. To
determine how important MgATP, MgADP and MgCl2 were in
forming the complex, and whether the nucleotides were also
bound in the complex, we performed the incubation of ePL kinase
with several different combinations of these compounds, and
carried out the final separation of the enzyme from the small
molecules in the absence of purine nucleotides. After the
separation, we analyzed the complexes for the presence of PLP,
MgATP and MgADP, after complete denaturation by 0.2 M
NaOH (see Experimental Procedures). The results are reported in
Table 2. PLP was always found to be present in the complex, while

To determine the rate of dissociation of PLP from the ePL
kinaseNPLP complex, we took advantage of the property that free
PLP does not elicit an optical signal in a CD spectrum because it is
a symmetrical molecule. But, when PLP is bound to B6 enzymes,
the asymmetric environment at the active site induces a CD signal
in PLP that can be either negative or positive [25]. A ePL
kinaseNPLP complex was obtained by incubating 130 mM ePL
kinase with 0.5 mM PL and 1 mM MgATP, and separated on a
sizing column in the absence of purine nucleotides. The CD
spectrum of the obtained ePL kinaseNPLP complex exhibits
negative ellipticity bands at about 330 nm and 415 nm (Fig. 5A,
curve (a)). To determine the rate of PLP dissociation from the
complex we followed the rate of decrease of the CD signal at

Table 1. Rate of formation of ePL kinaseNPLP complex in the presence of different substrates and productsa.
Rate of complex formation (min21)

Substrates and products added to ePL kinase
PL + MgATP

0.43

PLP + MgATP

0.13

PLP + MgADP

0.31

PLP

0.16

a
ePL kinase (90 mM) samples were incubated with different combinations of PL (150 mM), PLP (150 mM), MgATP (400 mM), MgADP (400 mM) and MgCl2 (0.2 mM).
Complex formation was measured at time intervals as described in Materials and Methods section. Values are the average of three independent measurements and the
standard deviation was less than 10%.
doi:10.1371/journal.pone.0041680.t001
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415 nm when the complex was incubated with a specific PLP
phosphatase (10 mM) [26]. As PLP dissociates from the complex,
the phosphatase rapidly converts it to PL and this results in a
decrease of the CD signal. The observed kinetics (Fig. 5B) shows
that the rate of dissociation is very slow (0.012 min21) and fits very
well to a first-order decay curve. The final CD spectrum after
120 min shows that only a fraction of the bound PLP was released
(Fig. 5A, curve (b)). Measurement of the residual PLP in the
sample showed that about 60% of the initially bound PLP was
present even after a 2-hour experiment. Very similar results were
obtained using alkaline phosphatase in place of PLP phosphatase.
In another experiment, an identical ePL kinaseNPLP complex was
reduced with NaBH4. This potent reductant is often used to
reduce the PLP aldimine double bond (absorbing at 420 nm) to a
single bond. The reduction is accompanied by a large spectral
change. Also in this case, the reduction of only a small fraction of
the enzyme-bound PLP was observed (as a decrease of the 420 nm
absorbing band and a concomitant appearance of a band at
around 325 nm). Evidently, there is a fraction of tightly bound
PLP that does not dissociate from ePL kinase and is not easily
accessible from the solvent by NaBH4.

Mechanism of Formation of ePL KinaseNPLP Complex
The spectrum of the ePL kinaseNPLP complex shown in Figure 3
shows absorption peaks at 336 nm and 420 nm. These absorbance
maxima are also represented in the CD spectra as observed in
Figure 5A. The peak at 420 nm is characteristic of a protonated
PLP aldimine and therefore clearly indicates that PLP is covalently
bound, albeit reversibly to a lysine residue of the enzyme [23]. The
absorbance of the peak at 336 nm could also be attributed to a
covalently bound PLP, most likely the carbinolamine intermediate
which occurs in the aldimine linkage formation (Fig. 6A). One has
to keep in mind that an aldimine linkage is a readily reversible
covalent bond and therefore PLP is still able to dissociate from the
enzyme. The structure of ePL kinase shows the presence of a lysine
residue, namely Lys229 (K229), near the active site. In the
published crystal structure of ePL kinase with bound PL, the side
chain of K229 is about 4.5 Å from PL, but its side chain can rotate
to place the e-amino group ,1.6 Å from the aldehyde group of
PL. (Fig. 6B) [11]. This suggests a possible conformational change
of the lysine side-chain position to form the Schiff-base linkage
with the PLP. We have not been able to obtain crystals of the ePL
kinaseNPLP complex to ascertain if PLP is actually bound to this
lysine residue. Therefore, we decided to change this residue to a
glutamine to determine if K229 was critical for catalytic activity,
enzyme inactivation, tight binding of PLP and the spectral
properties shown in Figures 3 and 5A.
Previous studies may have given erroneous kinetic constants for
ePL kinase because they were not appreciative of the rapid loss of
activity due to PLP inhibition, as shown in Figure 2. We have
more carefully determined the kinetic constants for the wild type
enzyme by determining the initial rate in the first few seconds
before inhibition becomes a factor. The results are shown in
Table 3. The K229Q mutant enzyme was expressed and purified
as described for the wild type enzyme. Kinetic constants were
determined and are recorded in Table 3. These results show that
K229 plays a role in both binding of substrates and catalysis but is
not essential for activity. Note that the affinity for MgATP in
K229Q enzyme is greater compared to wild type ePL kinase.
When the mutant enzyme is incubated with PL and MgATP and
passed down a sizing column, no PLP is found tightly bound as
shown in Figure 3 for wild type ePL kinase. Furthermore, unlike
wild type ePL kinase, incubation of K229Q with PL and MgATP
does not result in a rapid loss of activity (Fig. 7).

Reactivation of Inhibited ePL KinaseNPLP Complex
If the inactivation of ePL kinase takes place in an E. coli cell,
how does the kinase continue to function in order to generate
PLP? Is there a mechanism by which the tightly bound PLP is
removed to reactivate the enzyme? Previous studies with PNP
oxidase and PLP synthase have been shown to bind PLP tightly.
For both enzymes this tightly bound PLP was transferred to an
apo-B6 enzyme, apo serine hydroxymethyltransferase (apoSHMT) for PNP oxidase and aspartate aminotransferase for
PLP synthase [27,28]. To test if an apo-B6 enzyme could also
regenerate an active ePL kinase we added purified apo-E. coli
SHMT (eSHMT) and determined if the tightly bound PLP on
the kinase was transferred to the apo-eSHMT to form the active
holo-eSHMT. eSHMT is a good B6 enzyme to use since the
active enzyme forms an abortive complex with product glycine
and substrate tetrahydrofolate that exhibits an absorption peak
at 495 nm with a large molar absorbance coefficient [27]. The
rate of formation of this absorbing complex can be followed
continuously with time.
As shown in Figure 8, when an equivalent subunit concentration
of apo-eSHMT is added to ePL kinaseNPLP complex, there is a

Figure 5. Rate of dissociation of PLP from the ePL kinaseNPLP
complex. The rate of dissociation of PLP from the ePL kinaseNPLP
complex was followed by observing the change in optical activity of the
bound PLP at 37uC. Panel A: Spectra of the complex (60 mM) at time
zero (curve a) and after 120 min in the presence of 10 mM PLP
phosphatase (curve b). Panel B: measured decrease in optical activity
after addition of PLP phosphatase at 415 nm with time and as an
exponential process with rate constant of 0.012 min21.
doi:10.1371/journal.pone.0041680.g005
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Figure 6. Mechanism of reaction between PLP and the active site K229. A) A scheme showing the structures of the carbinolamine
intermediate and the enolimine form of the protonated PLP aldimine. B) Active site structure of the binary complex of ePL kinase and PL showing the
position of K229.
doi:10.1371/journal.pone.0041680.g006

prokaryotic and eukaryotic organisms; PL kinase, which is also
widely distributed in nature [3,11]; and PLP synthase, which is
found in plants and many microorganisms [30]. Both PNP oxidase
and PLP synthase have been shown to bind PLP tightly and to
transfer the tightly bound PLP to an apo-B6 enzyme [28,31]. This
report is the first study on the properties of the formation and
dissociation of a tightly bound PLP in ePL kinase.

transfer of PLP to form holo-eSHMT. The rate of transfer far
exceeds the rate of dissociation of PLP from the complex as
determined by CD studies (Fig. 5). Of interest is the observation
that only 50% of the tightly bound PLP is transferred, as suggested
by the effect of the addition of an excess of free PLP to apoeSHMT. The addition of a phosphatase did not reduce the
amount of transfer of PLP suggesting PLP was being transferred
directly without coming into contact with the phosphatases.
Although speculative, it is possible the PLP is not even released
into the solvent but directly channeled to apo-eSHMT. We
observed that some catalytic activity of PL kinase returns upon
transfer of the tightly bound PLP to apo-eSHMT but is much less
than the expected 50% (data not shown). Future studies are
focused on understanding in much more detail the mechanism of
transfer of PLP and the reactivation of PL kinase.

Discussion
There are three known enzymes in living systems that catalyze
the production of PLP: PNP oxidase [3,29], present in both

Table 3. Kinetic parameters for wild type and K229Q mutant
ePL kinase.

Km for MgATP
Km for PL (mM) (mM)

kcat (min21)

wild type

60

460

240

K229Q

384

122

26

Figure 7. Comparison of PLP formation with wild type and
K229Q ePL kinases. The kinetics of PLP formation catalyzed by ePL
kinase was followed at 388 nm upon addition (shown by the arrow) of
0.3 mM of wild type enzyme (continuous line) or 0.3 mM of K229Q
enzyme (dotted line). Each reaction contained 1 mM MgATP, 0.2 mM
MgCl2 and 1 mM PL, at 37uC.
doi:10.1371/journal.pone.0041680.g007

doi:10.1371/journal.pone.0041680.t003
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of specific and non-specific PLP phosphatases (Fig. 5A and B).
This slow rate cannot account for the order of magnitude faster
rate of transfer of the tightly bound PLP to apo-eSHMT.
Our results raise questions about the role of ePL kinase in vivo. The
observed inhibition mechanism and the transfer of PLP to apo-B6
enzymes may be a strategy to tune ePL kinase activity on the actual
requirements of the PLP cofactor. Moreover, since PLP is such a
reactive compound, having it bound tightly to ePL kinase would
afford protection against unwanted side reactions, in which it can be
dephosphorylated or form aldimines with free amino acids or eamino groups on lysine residues in non-B6 proteins. We observed
that the tightly bound PLP is protected from dephosphorylation by
either a specific PLP phosphatase or alkaline phosphatase. But if
protecting PLP from the unproductive side reactions is the purpose
of its tight binding, then there must be a mechanism by which PLP is
released to activate the newly synthesized apo-B6 enzymes, restoring
the catalytic turnover of the kinase.

Figure 8. Rate of transfer of PLP from PL kinaseNPLP to apo E.
coli serine hydroxymethyltransferase. Fraction of apo-eSHMT
(20 mM) being converted to holo-eSHMT with PLP (20 mM) (N–N). Fraction
of apo-eSHMT (20 mM) being converted to holo-eSHMT with an
equivalent amount of PL kinaseNPLP (20 mM) (m–m). Repeat of the
conversion of apo-eSHMT with free PLP (#–#) or PL kinaseNPLP (D–D)
to holo-eSHMT in the presence of 3 mM PLP phosphatase.
doi:10.1371/journal.pone.0041680.g008

Materials and Methods
Materials
All buffers, reagents and chromatography materials were of the
purest grade available and are the same as previously reported
[11,20]. ePL kinase was expressed, purified and stored as
previously described [11]. Calf intestine alkaline phosphatase
was purchased from Fermentas International Inc.

Three classes of enzyme competitive inhibitors have been
described [32]: those which inhibit rapidly, those which inhibit
rapidly followed by a slow conformational change, and those
which inhibit slowly. Classical competitive inhibitors act rapidly
and show a high affinity for the active site of the ground state
enzyme, whereas slow binding inhibitors show a high affinity for
an intermediate state of the enzyme. Slow binding inhibition is
characterized by an initial weak binding to the ground state
enzyme, followed by tighter binding to the transition state
structure. In general, this type of inhibition is considered more
physiologically relevant since upstream accumulation of the
substrate cannot relieve the inhibition brought about by this form
of inhibition [33].
The results presented here suggest that PLP is a slow tight
binding inhibitor of ePL kinase. The mechanism of inhibition
consists in the formation of a Schiff base between PLP and an
active site lysine residue (Fig. 6A). The inactivation of the enzyme
is faster when both PLP and MgADP are present, compared to
when PLP is present alone or together with MgATP (Fig. 4 and
Table 1). Therefore, the inhibition occurs more rapidly during the
catalytic turnover of the enzyme, in which the enzyme may go
through an intermediate state whose conformation favors the
covalent binding of PLP. It appears that during the catalytic cycle,
or when both PLP and MgADP are bound, the active site of ePL
kinase is in a conformation that places the e-amino group of K229
in a favorable position to form a covalent bond with C49 of PLP.
The position of K229 in the active site structure of the unliganded
ePL kinase is shown in Fig. 6B. Formation of an aldimine between
PLP and the e-amino moiety of K229 is suggested by the
absorption maximum at 420 nm (Fig. 3 inset) and by the failure of
PLP to bind tightly to K229Q ePL kinase and to inhibit its activity
(Fig. 7). The 336 nm absorbing band of the tightly bound PLP
(Fig. 3, inset) can be accounted for by several possible structures.
One of the most probable is a carbinolamine intermediate, which
occurs during the formation of the aldimine (Fig. 6A). In the
carbinolamine structure, the C49 carbon of PLP is tetrahedral
because of the addition of the e-amino moiety of K229 across the
double bond to oxygen. Another possible structure is the
enolimine tautomer of the PLP protonated aldimine also found
at the active site of PLP-dependent enzymes [25,34].
The rate of dissociation of PLP from the ePL kinaseNPLP
complex is very slow, as shown by the CD studies in the presence
PLoS ONE | www.plosone.org

Methods
All experiments were carried out in 20 mM potassium HEPES,
pH 7.5, containing 0.2 mM MgCl2 except when otherwise stated.
The catalytic activity of ePL kinase was determined spectophotometrically at 37uC by observing the initial increase in absorbance
at 388 nm during the conversion of PL to PLP [20].

Purification of PLP Phosphatase
Human brain PLP phosphatase cDNA cloned in pET19b was
kindly provided by Dr. Anette Bøe, University of Bergen, Norway
[35]. The plasmid was transformed into Escherichia coli strain Rosetta
(lDE3) pLysS. The recombinant cells were grown at 37uC in LB
broth with ampicillin (50 mg/ml) and chloramphenicol (34 mg/ml)
until OD600 was about 1.0 and induced with 50 mM isopropyl-b-Dthiogalactopyranoside (IPTG). The cells were grown for additional
24 hours at 18uC and then harvested by centrifugation. The Histagged enzyme was released by homogenization in 50 mM sodium
phosphate buffer, pH 8, containing 300 mM NaCl and 10 mM
imidazole. After centrifugation the cell extract was added to a 10 ml
Ni-NTA agarose column (Qiagen) and the column was washed
sequentially with 20, 30, 50, 75, 150 mM imidazole buffers, pH 8,
until the absorbance at 280 nm was less than 0.1. The PLP
phosphatase was then eluted with 250 mM imidazole buffer. The
purified enzyme was dialyzed against 160 mM NaCl and 4 mM
MgCl2 in 40 mM sodium BES, pH 7.0 for 4 hours. A second
dialysis in the same buffer, except with 80 mM NaCl, was continued
overnight. The enzyme was stored at 220uC. About 20 mg of 90%
pure enzyme was obtained per liter of culture. Activity was
determined by monitoring the decrease in absorbance at 388 nm
during the conversion of PLP to PL [4].

Preparation of K229Q ePL Kinase
In order to avoid any contamination from wild type ePL kinase
from the host cells, the K229Q mutant was expressed as a Histagged protein and purified by affinity chromatography. The
addition of the His-tag at the C-terminus of ePL kinase was
obtained by subcloning the coding sequence of wild type ePL
7
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which PLP has negligible absorbance) of 35,416 M21 cm21,
which was determined from the absorption spectrum of a protein
sample whose concentration was previously determined in buffer
(extinction coefficient at 278 nm of 28,850 M21 cm21) [20]. The
concentration of PLP in the buffer at pH 7.5 was calculated using
an extinction coefficient at 388 nm of 5305 M21 cm21. This
coefficient was derived from the absorption spectrum of a PLP
sample whose concentration was determined in NaOH.

kinase [20] into pET28a plasmid (Novagen), between NdeI and
EcoRI restriction sites.
The K229Q mutant was prepared by site-directed mutagenesis
using the pET28-ePL kinase construct as template, by the QuickChangeTM method from Stratagene. Two oligonucleotides (synthesized by MWG-Biotech) containing the mutations were used as
primers:
59-GGTTAAAACTGACCTGCAAGGGACTGGCGACC-39 and its complementary oligonucleotide (the mutated
bases are underlined). E. coli DH5a cells were transformed and
used to amplify the mutated plasmid. Both strands of the coding
region of the mutated gene were sequenced. The only differences
with respect to wild type were those intended.
Enzyme expression of the His-tagged form of the enzyme,
performed using the HMS174(lDE3) strain of E. coli, was induced
by adding 0.2 mM IPTG. After incubation at 28uC with constant
agitation for 20 h, cells were harvested and suspended in 50 mM
sodium phosphate buffer, pH 8, containing 0.3 M NaCl. Cells
were ruptured by sonication. Following the addition of DNase I
(0.02 mg/ml), the lysate was centrifuged, and the supernatant was
loaded on a 25 ml Ni-NTA agarose column, equilibrated with lysis
buffer. The column was washed with the same buffer, containing
40 mM imidazole, and the enzyme was then eluted with a 400-ml
linear gradient of imidazole from 40 mM to 0.5 M. Fractions
containing the enzyme were detected by SDS-polyacrylamide gel
electrophoresis, pooled and dialyzed against 20 mM potassium
HEPES, pH 7.5. The His-tagged form of the wild type enzyme
was also purified and characterized with respect to its catalytic
properties, which were found to be identical to the original form of
the enzyme.

Determination of ATP and ADP Concentration in ePL
KinaseNPLP Complexes
The complexes were obtained by incubating 130 mM ePL kinase
samples with different combinations of PLP, PL, MgATP,
MgADP and MgCl2 as detailed in Table 2, at 37uC for 1 hour
in 20 mM potassium HEPES, pH 7.5. The samples were then
passed through a G-50 Sephadex column (1.3 cm624 cm) that
had been previously equilibrated with 20 mM potassium HEPES,
pH 7.5, containing 0.5 mM MgCl2 and eluted with the same
buffer. Fractions containing ePL kinase were pooled. PLP and
protein concentrations were measured as described above. In
order to determine nucleotide concentration, 600 mL of sample
was treated as follows. The protein was denatured by the addition
of 0.2 M NaOH in order to allow the release of protein-bound
molecules. Addition of 0.2 M HCl neutralized the solution
followed by centrifugation to remove the protein precipitate.
The supernatant (450 mL) was transferred in a clean tube and
assayed for the presence of ATP and ADP. ADP concentration
was measured, by coupling pyruvate kinase and lactate dehydrogenase reactions, from the absorbance change at 340 nm due to
NADH oxidation. A typical assay, carried out at 37uC in 20 mM
potassium HEPES, pH 7.5, in a final volume of 600 mL, contained
450 mL of the complex sample, 2 mM phosphoenolpyruvate,
0.25 mM NADH, 18 units of D-lactate dehydrogenase and
10 units of pyruvate kinase. ATP concentration was determined
using human PL kinase activity, measuring the absorbance change
at 388 nm due to PLP formation from PL. Assays, carried out at
37uC in 20 mM potassium HEPES, pH 7.5, in a final volume of
600 mL, contained 450 mL of the complex sample, 0.17 mM PL
and 8 mM PL kinase. Both assays had been previously validated
using commercial nucleotide samples of known concentrations,
which ranged from 1.5 mM to 40 mM, obtaining two calibration
curves for ATP and ADP measurements. The minimum
detectable nucleotide concentration was estimated to be around
1.5 mM for both assays.

Rate of Formation of ePL KinaseNPLP Complex in the
Presence of Different Substrates and Products
The rates of formation of ePL kinaseNPLP complex were
determined by small Sephadex G-50 spin columns as follows. One
ml plastic syringes with a glass wool plug were filled to the 0.5 ml
mark with Sephadex G-50 in 50 mM potassium HEPES, pH 7.5.
In an Eppendorf tube, 90 mM ePL kinase was incubated for
various times with 0.4 mM MgATP or MgADP, 0.150 mM PL or
PLP, 0.2 mM MgCl2, in 0.1 ml reaction volume at 37uC. After
incubation, each sample was placed on the G-50 column that was
equilibrated with buffer, which contained either 1 mM MgATP or
1 mM MgADP and 0.2 mM MgCl2 in 20 mM potassium HEPES
buffer, pH 7.5, at 4uC. In the experiment in which only PLP was
present, the nucleotides were omitted from the buffer. The sample
was allowed to soak into the column. To each column, 400 ml of
equilibration solution at 4uC was added and the plastic syringes
(placed in a glass test tube) were inserted in a swinging bucket
centrifuge and rotated at about 150 rpm. The buffer containing
the protein elutes into the glass tube and the small molecules
remain on the column. The 400 ml of eluted sample is then placed
in a 1 cm cuvette and the spectrum recorded. The total time to
separate ePL kinase from small molecules is about 3 min. Controls
show that 8963.5% of ePL kinase eluted in the 400 ml and less
than 2% of the excess PL and PLP were eluted.

Rate of Dissociation of PLP from the ePL KinaseNPLP
Complex
The CD spectrum of bound PLP in the ternary complex was
used to determine the rate of dissociation of PLP. Bound PLP in
the complex gives negative bands at about 336 nm and 415 nm,
but free PLP does not exhibit a CD signal since it is a symmetrical
molecule. A 60 mM solution of ePL kinaseNPLP complex was
placed in a 1 cm cell and the signal at 415 nm followed with time
at a bandwidth of 5 nm at 37uC. Included in the sample was a
10 mM solution of PLP phosphatase or alkaline phosphatase to
rapidly convert any released PLP to PL.

Stoichiometry of ePL KinaseNPLP Complexes
The stoichiometry of the formation of the ePL kinaseNPLP
complex was determined by adding NaOH to a final concentration of 0.2 M to denature the protein and release the tightly bound
PLP. The absorbance at 388 nm was used to determine the
concentration of the cofactor, that in 0.2 M NaOH exhibits a
molar extinction coefficient of 6600 M21 cm21 [7]. The concentration of ePL kinase in the complex was also determined in 0.2 M
NaOH, using an extinction coefficient at 292 nm (a wavelength at
PLoS ONE | www.plosone.org

Determination of PL Kinase Kinetic Constants for Wild
Type and K229Q ePL Kinases
All assays were performed at 37uC in a 1 cm thermostated
cuvet. The increase of absorbance at 388 nm, due to the difference
between
PLP
production
and
PL
consumption
(e = 5020 M21 cm21 at pH 7.5), was monitored for about 60 s
8
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in an Agilent 8453 spectrophotometer. The very first initial
velocity was used to calculate kinetic parameters in order to avoid
enzyme inhibition. Km and kcat values for ATP and PL were
determined as previously described [20].

following the absorbance at 495 nm. To determine the fraction of
holo-eSHMT formed a control was performed where the PL
kinase complex was replaced with 25 mM PLP, which would fully
saturate the apo-eSHMT giving the A495nm for fully saturated
holo-eSHMT. Each of these two experiments was duplicated in the
presence of 3 mM PLP phosphatase that was added to the reaction
solution prior to starting the transfer with either free PLP or PL
kinaseNPLP.

Transfer of PLP from the ePL KinaseNPLP Complex
The complex was prepared as described in the section on the
analysis of ADP and ATP. In a 1 ml cuvette in HEPES buffer,
pH 7.5, 37uC, the following was added; glycine (50 mM),
tetrahdyrofolate (100 mM); and apo-eSHMT (20 mM). The transfer was started by the addition of the 20 mM PL kinaseNPLP.
Transfer of PLP from the PL kinase complex was followed by the
formation of the holo-SHMTNGlyNtetrahdyrofolate abortive complex that absorbs at 495 nm [27]. The first experiment was to
determine if any of the PLP in the complex was transferred by
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